Tech Company Financing Transactions
BioEclipse Therapeutics Funding Round
Revelis Capital, DEFTA Partners and Foothill Ventures participated in a $7.7 million Series A funding round for BioEclipse Therapeutics. The round was announced on 6/25/2019.
Transaction Overview
Company Name
Announced On
6/25/2019
Transaction Type
Venture Equity
Amount
$7,700,000
Round
Series A
Investors
Revelis Capital (Lead Investor) (Oliver Hopkinson)
Proceeds Purpose
BioEclipse plans to use proceeds from the Series A-1 financing to initiate human trials of CRX-100, BioEclipse's patented, first-in-class, intravenous, tumor targeted combination immunotherapy.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
329 Oyster Point Blvd. 3rd Floor S.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
BioEclipse Therapeutics is an emerging, clinical-stage biopharmaceutical company committed to delivering first-in-class, curative immune-oncology therapeutics to patients with cancer. Our focus is on currently untreatable cancers where our unique approach may be able to address needs of patients with cancers that most think not possible.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Catherine Sohn
Chief Executive Officer
Pamela Contag
Chief Financial Officer
Benjamin Carter
Co-Founder
Christopher Contag
Co-Founder
Robert Negrin
Browse more venture capital transactions:
Prev: 6/25/2019: Alma venture capital transaction
Next: 6/25/2019: Corinth MedTech venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs